ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 883,41
-0,01%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Actualités

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AUPH
DateHeureSourceTitreSymboleSociété
02/05/202412h00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202412h00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202412h00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
16/04/202416h48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202412h00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202412h00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/03/202422h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202414h30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
27/02/202414h30Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202422h19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202412h16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202412h00Business WireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder ValueNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/02/202421h27Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/02/202414h30Business WireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
05/01/202412h00Business WireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
20/12/202312h00Business WireAurinia Submits IND Application to US Food & Drug Administration for AUR 200NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/11/202312h00Business WireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNASDAQ:AUPHAurinia Pharmaceuticals Inc
07/11/202316h30Business WireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202323h00Business WireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202311h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/11/202311h00Business WireAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
26/10/202321h00Business WireAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
19/10/202316h31Business WireCORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
19/10/202312h00Business WireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023NASDAQ:AUPHAurinia Pharmaceuticals Inc
13/10/202318h00Business WireAurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)NASDAQ:AUPHAurinia Pharmaceuticals Inc
22/09/202322h31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
21/09/202312h00Business WireAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT CapitalNASDAQ:AUPHAurinia Pharmaceuticals Inc
21/08/202312h00Business WireAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic PipelinesNASDAQ:AUPHAurinia Pharmaceuticals Inc
03/08/202312h00Business WireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH

Dernières Valeurs Consultées

NYSE
MCD
McDonalds
NYSE
NKE
Nike
EU
EN
Bouygues
EU
VK
Vallourec
NASDAQ
MSFT
Microsoft
EU
BEL20
Bel 20
USI
USTECH100
US Tech 100
EU
VIV
Vivendi
EU
CS
Axa
NYSE
KO
Coca Cola
EU
DG
Vinci
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés